NR3C2 and atrial fibrillation: Less patients had atrial fibrillation (27%) than those in recent HFrEF trials, but prescription rates of background therapy with beta‐blockers (96%), angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (95%), mineralocorticoid receptor antagonists (76%), and diuretics (87%) were high and similar.